

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**CSPC PHARMACEUTICAL GROUP LIMITED**

**石藥集團有限公司**

*(Incorporated in Hong Kong with limited liability)*

**(Stock Code: 1093)**

**UNAUDITED FINANCIAL INFORMATION OF  
CSPC INNOVATION PHARMACEUTICAL CO., LTD.  
FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2025**

In compliance with the relevant requirements of Shenzhen Stock Exchange, CSPC Innovation Pharmaceutical Co., Ltd. (“**CSPC Innovation**”), a subsidiary of CSPC Pharmaceutical Group Limited (the “**Company**”) listed on the ChiNext of Shenzhen Stock Exchange (Stock Code: 300765), published its unaudited third quarterly report for the nine months ended 30 September 2025 (the “**2025 Third Quarterly Report**”) on 27 October 2025 on the information disclosure webpage of Shenzhen Stock Exchange’s website at <http://www.szse.cn/disclosure/listed/notice/index.html>. CSPC Innovation’s financial information was prepared in accordance with the China Accounting Standards for Business Enterprises.

Set out in the appendices to this announcement (the “**Appendices**”) is the principal financial data of CSPC Innovation extracted from the 2025 Third Quarterly Report prepared in Chinese. In case of any inconsistency between the Chinese version and the English version, the Chinese version shall prevail.

**Shareholders and potential investors of the Company are reminded that the financial information of CSPC Innovation in the 2025 Third Quarterly Report and in the Appendices are unaudited consolidated financial information of CSPC Innovation for the nine months ended 30 September 2025, rather than that of the Company. They should exercise caution when dealing in the securities of the Company.**

By Order of the Board  
**CSPC Pharmaceutical Group Limited**  
**CAI Dong Chen**  
*Chairman*

Hong Kong, 27 October 2025

*As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin and Mr. CHEN Weiping as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as independent non-executive directors.*

## APPENDIX I

### KEY ACCOUNTING DATA AND FINANCIAL INDICATORS

*Currency: RMB*

|                                                                                                                   | Current reporting period                   | Increase/decrease of the current reporting period compared to the corresponding period of the last year | From the beginning of the year to the end of the reporting period                          | Increase/decrease from the beginning of the year to the end of the reporting period compared to the corresponding period of the last year |
|-------------------------------------------------------------------------------------------------------------------|--------------------------------------------|---------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------|
| Operating revenue (Yuan)                                                                                          | 543,456,419.92                             | 7.18%                                                                                                   | 1,593,014,097.66                                                                           | 7.71%                                                                                                                                     |
| Net profit attributable to shareholders of the listed company (Yuan)                                              | -21,302,733.89                             | -1,025.45%                                                                                              | -24,048,877.47                                                                             | -117.26%                                                                                                                                  |
| Net profit attributable to shareholders of the listed company after deducting non-recurring profit or loss (Yuan) | -23,676,807.75                             | -1,147.56%                                                                                              | -64,820,945.93                                                                             | -147.40%                                                                                                                                  |
| Net cash flow generated from operating activities (Yuan)                                                          | —                                          | —                                                                                                       | -175,121,559.93                                                                            | 81.67%                                                                                                                                    |
| Basic earnings per share (Yuan/share)                                                                             | -0.0153                                    | -865.00%                                                                                                | -0.0173                                                                                    | -117.39%                                                                                                                                  |
| Diluted earnings per share (Yuan/share)                                                                           | -0.0153                                    | -865.00%                                                                                                | -0.0173                                                                                    | -117.39%                                                                                                                                  |
| Weighted average return on net assets                                                                             | -0.58%                                     | -0.64%                                                                                                  | -0.65%                                                                                     | -3.47%                                                                                                                                    |
|                                                                                                                   | At the end of the current reporting period | At the end of the last year                                                                             | Increase/decrease from the end of the last year to the end of the current reporting period |                                                                                                                                           |
| Total assets (Yuan)                                                                                               | 6,210,880,638.20                           | 6,022,115,755.32                                                                                        | 3.13%                                                                                      |                                                                                                                                           |
| Equity attributable to shareholders of the listed company (Yuan)                                                  | 3,687,757,832.28                           | 3,730,544,275.59                                                                                        | -1.15%                                                                                     |                                                                                                                                           |

## APPENDIX II

### NON-RECURRING PROFIT OR LOSS ITEMS AND AMOUNTS

*Unit: Yuan      Currency: RMB*

| Items                                                                                                                                                                                                                                                                                                  | Amount for the current reporting period | Amount for the period from the beginning of the year to the end of the reporting period | Description |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------|-----------------------------------------------------------------------------------------|-------------|
| Gains/losses on disposal of non-current assets (including the portion offset with the provision for impairment of assets)                                                                                                                                                                              | -35,319.93                              | 1,753,198.41                                                                            |             |
| Government grants recognised in profit or loss for the current period (excluding those closely related to the company's normal business operations, complied with national policies, granted according to established standards, and continuously affecting the company's profit or loss)              | 4,249,218.58                            | 71,944,745.16                                                                           |             |
| Profit or loss from changes in fair value of financial assets and financial liabilities and profit or loss from disposal of financial assets and financial liabilities held by non-financial enterprises, other than effective hedging activities related to normal business operations of the company | 2,085,625.00                            | 5,768,013.23                                                                            |             |
| Non-operating income and expenses other than the items above                                                                                                                                                                                                                                           | -2,040,396.16                           | -3,890,349.65                                                                           |             |
| Less: Impact of income tax                                                                                                                                                                                                                                                                             | 405,630.10                              | 1,057,896.40                                                                            |             |
| Impact of minority interests (after tax)                                                                                                                                                                                                                                                               | 1,479,423.53                            | 33,745,642.29                                                                           |             |
| Total                                                                                                                                                                                                                                                                                                  | 2,374,073.86                            | 40,772,068.46                                                                           | —           |

## APPENDIX III

### CHANGES IN AND REASONS FOR CHANGES IN KEY ACCOUNTING DATA AND FINANCIAL INDICATORS

*Unit: Yuan      Currency: RMB*

#### 1. Major items of consolidated balance sheet

| Items                | 30 September 2025 | 31 December 2024 | Changes | Reasons for changes                                                                                                                                                               |
|----------------------|-------------------|------------------|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Trade receivables    | 466,532,344.78    | 314,097,126.88   | 48.53%  | Mainly due to the increase in operating revenue and the outstanding accounts receivables from credit sales within the credit period that have yet to be collected.                |
| Other receivables    | 8,908,342.69      | 2,047,522.08     | 335.08% | Mainly due to the outstanding payments from the transfer of equipment that have yet to be received.                                                                               |
| Bills payables       | 136,322,557.04    | 92,881,577.34    | 46.77%  | Mainly due to the increase in the banker's acceptances issued by the company.                                                                                                     |
| Trade payables       | 474,991,650.54    | 303,326,595.53   | 56.59%  | Mainly due to the increase in outstanding payments for research and development activities as a result of the accelerated progress of biopharmaceutical research and development. |
| Contract liabilities | 30,138,781.16     | 18,683,904.44    | 61.31%  | Mainly due to the increase in advance receipts of the company.                                                                                                                    |
| Deferred income      | 141,560,402.73    | 90,487,251.91    | 56.44%  | Mainly due to the increase in the receipt of government grants by the company.                                                                                                    |

#### 2. Major items of consolidated income statement

| Items                             | January to September 2025 | January to September 2024 | Changes | Reasons for changes                                                                                                                                                  |
|-----------------------------------|---------------------------|---------------------------|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Selling expenses                  | 201,949,706.57            | 107,924,429.63            | 87.12%  | Mainly due to the increase in marketing investment in the biopharmaceutical business.                                                                                |
| Research and development expenses | 683,435,255.69            | 456,957,233.20            | 49.56%  | Mainly due to the increase in the research and development expenses as a result of Megalith Biopharma's increased investment in research and development innovation. |
| Other gains                       | 74,444,840.99             | 7,908,564.12              | 841.32% | Mainly due to the increase in the receipt of government grants during the year.                                                                                      |

#### 3. Major items of consolidated statement of cash flows

| Items                                             | January to September 2025 | January to September 2024 | Changes | Reasons for changes                                                                                                                                                                   |
|---------------------------------------------------|---------------------------|---------------------------|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Net cash flow generated from operating activities | -175,121,559.93           | -955,575,497.94           | 81.67%  | Mainly due to the settlement of research and development expenses of Megalith Biopharma that had been outstanding from previous periods in the corresponding period of the last year. |
| Net cash flow generated from investing activities | -244,872,397.40           | -918,868,799.42           | 73.35%  | Mainly due to the redemption of the company's structured bank deposits upon maturity.                                                                                                 |
| Net cash flow generated from financing activities | 340,066,748.32            | -607,138,248.40           | 156.01% | Mainly due to the decrease in the company's cash dividends and the acceptance of loans from related parties by Megalith Biopharma during the reporting period.                        |